We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Roche NimbleGen and BioDiscovery Form Strategic Alliance to Enhance CGH Microarrays, Software and Services

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Roche NimbleGen Inc., a company of Roche Applied Science, announced that it has formed a strategic alliance with BioDiscovery, Inc. to offer complete solutions to comparative genomic hybridization (CGH) microarray customers.

The high-density 2.1 million probe (HD2) arrays of Roche NimbleGen combined with proprietary software, Nexus Copy Number, of BioDiscovery bring power and ease in whole-genome CGH analysis.

As part of this alliance Roche NimbleGen and BioDiscovery will co-market and co-promote their products and services to scientists worldwide. The companies also plan to present data generated from NimbleGen CGH arrays using Nexus software of BioDiscovery to the research community through a series of seminars.

"This alliance with BioDiscovery will enable Roche NimbleGen to significantly enhance the customer experience by providing complete data analysis solutions for our customers using NimbleGen arrays for CGH analysis. At the same time we are excited about the opportunity to develop a strong business relationship with BioDiscovery in offering complete solutions to our customers in genomics and life sciences," said Srini Ramachandra, Senior Director for Software Marketing at Roche NimbleGen.